Emerging Company Profile: Candel Therapeutics, formerly known as Advantagene, has hired a new leadership team and is aiming for a Phase III data read-out in prostate cancer in 2023.
View Article: https://scrip.pharmaintelligence.informa.com/SC143448/Candel-Aims-High-In-Next-Stage-Of-Cancer-Immunotherapy-Mission
contact@paulpetertak.com
Privacy Policy
© Paul Peter Tak.All rights reserved.
LinkedIn
Wiki
Google Scholar
Pub Med
